11-hydroxy-delta-9-tetrahydrocannabinol

11-hydroxy-delta-9-tetrahydrocannabinol is the principal active metabolite of delta-9-tetrahydrocannabinol (THC), produced in the liver as a result of THC metabolism via cytochrome P450 (primarily CYP2C9 and CYP3A4) after oral or inhaled cannabis intake[1][2][4]. It exhibits significantly higher potency and binding affinity to the cannabinoid receptor CB1 compared to parent THC (Ki ≈ 0.37 nM vs. 35 nM for THC), contributing to its pronounced psychoactive effects[1][2][4]. 11-hydroxy-THC is responsible for much of the enhanced potency and lasting effects observed after oral cannabis consumption, as more is generated through hepatic first-pass metabolism[2][4]. Pharmacologically, it is a partial agonist at the cannabinoid receptor CB1, and, in research settings, produces psychoactive and pharmacological effects in humans lasting several hours after intravenous administration[3][1][5]. There is some evidence it might possess anti-inflammatory activity, and in vitro, it has shown inhibitory activity against certain viral proteases[1][4]. No data is available on specific manufacturer or originator companies, as this substance is a human metabolite, not a marketed pharmaceutical.

Other names

11-hydroxy-THC11-hydroxy-delta-9-THC11-OH-delta-9-THC11-OH-THC7-OH-delta-1-THC